In a health decision room, clinical evidence rarely speaks for itself. Decision-makers must integrate effectiveness, safety, costs, equity, acceptability, feasibility and organizational impact. That combination demands method.

HTA assessment frameworks turn that deliberation into an explicit process. They help organize questions, evaluate evidence, document judgments and explain why a technology receives coverage, conditional coverage or rejection. The goal is to reduce arbitrariness and increase transparency [1].

For market access teams, understanding these frameworks is practical. A dossier that anticipates the decision-maker's logic reduces friction, responds better to objections and speeds up review.

What an HTA assessment framework is

Health technology assessment frameworks, or HTA for its acronym in English, are methodological structures for moving from evidence to recommendation. Unlike a cost-effectiveness model, which produces a numerical result, an assessment framework organizes the entire conversation.

The framework defines which criteria are considered, what evidence is used for each criterion, how uncertainty is documented and how trade-offs are justified. In practice, it helps a complex decision become reviewable, discussable and defensible.

The most relevant international frameworks for access are GRADE Evidence-to-Decision, the EUnetHTA Core Model, WHO-INTEGRATE and multi-criteria decision approaches, known as MCDA.

GRADE Evidence-to-Decision: organizing the deliberation

GRADE EtD extends the GRADE logic from assessing certainty of evidence toward health decisions. Its purpose is to help panels and authorities use evidence in a structured and transparent way in clinical guidelines, coverage decisions and health system recommendations [1].

The process is usually organized into three moments.

Framing the question: defines population, intervention, comparator and relevant outcomes.
Assessing the evidence: analyzes benefits, harms, certainty, patient values, resource use, cost-effectiveness, equity, acceptability and feasibility.
Conclusion: translates the judgments into a recommendation, which may be broad coverage, restricted coverage, coverage with additional evidence or no coverage.

The usefulness of GRADE EtD lies in making the reasoning visible. A technology may have solid clinical evidence and, at the same time, raise equity concerns if it can only be implemented in high-complexity urban centers. The framework forces that conflict to be documented and to explain how it is resolved [2].

EUnetHTA Core Model: multidimensional assessment

The EUnetHTA Core Model was developed to facilitate shared and comparable assessments in Europe. Its structure combines an ontology of questions, methodological guidance and a common reporting format [3].

The model evaluates clinical and non-clinical dimensions. Its domains include:

Health problem and current use of the technology.
Description and technical characteristics.
Safety.
Clinical effectiveness.
Costs and economic evaluation.
Ethical aspects.
Organizational aspects.
Social aspects.
Legal aspects.

Its strength is breadth. It evaluates the technology as part of a system, not as an isolated product. Its challenge is the operational burden: applying all domains can be demanding for agencies with few resources or short timelines.

WHO-INTEGRATE: context, equity and sustainability

WHO-INTEGRATE was designed for public health, health system and health policy decisions. Its value for Latin America lies in its emphasis on context, rights, equity and sustainability [4].

The framework organizes the deliberation into six substantive criteria:

Balance of benefits and harms.
Human rights and sociocultural acceptability.
Equity, equality and non-discrimination.
Social implications.
Financial and economic implications.
Feasibility and health system considerations.

This approach is useful when the question combines effectiveness, distributive justice, available infrastructure and sustainability in fragmented systems with limited budgets.

MCDA: making the weights of the decision explicit

Multi-criteria decision analysis, or MCDA, formalizes the assessment of several dimensions through criteria, scores and weights. ISPOR describes it as a family of methods useful when decisions must balance multiple and sometimes conflicting objectives [5].

In HTA, an MCDA can assign weights to criteria such as effectiveness, safety, disease severity, equity, cost and budget impact. It then scores each technology against those criteria and calculates an aggregate result.

The advantage is transparency. The decision-maker sees what weighs most and how the recommendation changes when the weights change. The risk lies in false precision. Turning ethical or distributive conflicts into a number can hide discussions that should remain deliberative. That is why ISPOR recommends using MCDA with clear rules for design, implementation and review [6].

Latin America: a fragmented methodological reality

The region does not have a single standard. Brazil has CONITEC and a more formalized HTA process within the Unified Health System. Other countries have advanced in technology assessment, but with different levels of institutionalization, technical capacity and transparency.

This requires adapting the evidence strategy country by country. A dossier that works in a formal process may be oversized in a market with less structured assessment. At the same time, a weak dossier may fail in an agency that requires certainty of evidence, economic analysis and justification of implementation.

The key is to identify the decision-maker's real logic. When the explicit framework does not exist, it must be inferred by reviewing previous decisions, criteria used, frequent objections and the type of evidence the authority usually accepts.

How to prepare evidence aligned with the decision-maker's framework

An access dossier must speak the methodological language of the one who decides. This requires working from the framework and not from a generic presentation of data.

Identify the target process: confirm whether the authority uses GRADE, its own model, MCDA, internal guidelines or ad hoc review.
Map the evidence by criterion: organize effectiveness, safety, costs, budget impact, equity and feasibility according to the framework.
Anticipate implementation: explain required infrastructure, availability of professionals, logistics, monitoring and access barriers.
Show trade-offs: present honestly where the technology wins, where it has uncertainty and what measures can reduce that uncertainty.
Prepare scenarios: include coverage alternatives, restrictions, subgroups and generation of additional evidence.

The role of technology in applying HTA frameworks

Applying an HTA framework can take weeks: extracting evidence, rating certainty, building tables, mapping outcomes, synthesizing patient preferences and preparing appendices. Technology can accelerate that operational burden.

AI and automation tools can support data extraction, gap identification, generation of structured tables and adaptation of dossiers to the target country's framework. Their value lies in freeing up time so the team can focus on the evidence strategy, the trade-offs and the responses to predictable objections, always under expert deliberation.

Conclusion

HTA assessment frameworks make the path between evidence and decision visible. GRADE EtD, EUnetHTA, WHO-INTEGRATE and MCDA offer different ways of organizing a complex conversation.

In Latin America, where processes have different levels of maturity, mastering these frameworks is an access advantage. It allows designing clearer dossiers, anticipating difficult questions and presenting evidence in a way aligned with the decision-maker's logic.

At Quantus, we work with market access, HEOR and medical affairs teams to structure clinical, economic and contextual evidence in a way that is useful for real coverage decisions. If you want to align your dossier with the assessment framework of a specific market, write to us.

Sources

[1] Alonso-Coello, P., Schünemann, H. J., Moberg, J., et al. GRADE Evidence to Decision (EtD) frameworks: A systematic and transparent approach to making well informed healthcare choices. BMJ. 2016;353:i2016. Available at: https://www.bmj.com/content/353/bmj.i2016

[2] Parmelli, E., Amato, L., Oxman, A. D., et al. GRADE Evidence to Decision (EtD) framework for coverage decisions. International Journal of Technology Assessment in Health Care. 2017;33(2):176-182. Available at: https://www.cambridge.org/core/journals/international-journal-of-technology-assessment-in-health-care/article/grade-evidence-to-decision-etd-framework-for-coverage-decisions/B945890C1CCB8AF8CA4CC1903D2752CC

[3] Kristensen, F. B., Lampe, K., Chase, D. L., et al. The HTA Core Model: 10 years of developing an international framework to share multidimensional value assessment. Value in Health. 2017;20(2):244-250. Available at: https://www.valueinhealthjournal.com/article/S1098-3015(16)34220-6/fulltext

[4] Rehfuess, E. A., Stratil, J. M., Scheel, I. B., Portela, A., Norris, S. L., & Baltussen, R. The WHO-INTEGRATE evidence to decision framework version 1.0. Health Research Policy and Systems. 2019;17:55. Available at: https://health-policy-systems.biomedcentral.com/articles/10.1186/s12961-019-0452-6

[5] Thokala, P., Devlin, N., Marsh, K., et al. Multiple Criteria Decision Analysis for Health Care Decision Making: An Introduction. Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health. 2016;19(1):1-13. Available at: https://doi.org/10.1016/j.jval.2015.12.003

[6] Marsh, K., IJzerman, M., Thokala, P., et al. Multiple Criteria Decision Analysis for Health Care Decision Making: Emerging Good Practices. Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health. 2016;19(2):125-137. Available at: https://doi.org/10.1016/j.jval.2015.12.016

[7] World Health Organization. HTA Country Area Profile: Brazil. 2020-2021. Available at: https://cdn.who.int/media/docs/default-source/health-economics/hta-country-profiles-2020-21/hta-country_area-profile_brazil.pdf